GC Biopharma (006280) Stock Outlook 2026: Can a Plasma Powerhouse Crack the US Market?
A qualitative deep dive into the 2026 outlook for GC Biopharma (KRX: 006280), Korea's plasma-products leader. We cover the FDA approval and US market push of its immunoglobulin ALYGLO as the core growth catalyst, the vaccine, rare-disease (Hunterase), prescription and consumer-health segments, plasma cost and R&D pressures, earnings volatility and valuation risk, plus practical framing for international investors.
GC Biopharma 006280 Korea Stocks
